Healthcare division has signed a $25 mil. agreement to acquire complete assets of Gum Tech's gum business, firm announces March 15. Under the deal, Wrigley will obtain rights to Gum Tech's manufacturing facility and plant as well as existing manufacturing contracts. Gum Tech will retain its interest in Gel Tech and its joint venture with Swedish Match. Wrigley said the acquisition will enable its new healthcare division to more quickly and cost effectively develop innovative products than it would have by building its own facility. Wrigley Healthcare began shipping Surpass antacid chewing gum, its first OTC product, Feb. 19 (1"The Tan Sheet" Feb. 19, p. 8)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.
Pediatric Advisory Committee will weigh the FDA's recommendation that routine safety monitoring continue for Merck & Co's Gardasil and Sanofi's Fluzone and Dengvaxia despite a political climate that has been unkind to vaccines.
Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.